Legend Biotech Stock Jumps on Full Response in Small Trial as Traders React Quickly
Legend Biotech shares jumped over 35% midday Tuesday in New York after the company released early data on a new blood-cancer drug that attempts to generate cancer-fighting immune cells inside patients. The stock was last at $34.48, close to its session peak of $35.33, with trading volume well above normal.
